COVID-19 presents an unprecedented challenge to the global life sciences industry. The UK and EU regulators have worked to provide up-to-date guidance in response to the evolving crisis, as well as to support research and development (R&D) that they hope will contain the impact of the spread. The regulators must continue to coordinate in order to maximize clarity in this uncertain environment in which the far-reaching consequences of the pandemic are only just starting to manifest.
This Update provides guidance as to the response of UK and EU regulators so far in the areas of clinical trials, inspections and the continuity of supply in medicinal products and medical devices, as well as the proposed postponement of implementation of the medical device regulation (MDR) and in vitro diagnostics regulation (IVDR). We also summarize key R&D initiatives at a UK and EU level.
Sidley Austin LLP provides this information as a service to clients and other friends for educational purposes only. It should not be construed or relied on as legal advice or to create a lawyer-client relationship.
Attorney Advertising - For purposes of compliance with New York State Bar rules, our headquarters are Sidley Austin LLP, 787 Seventh Avenue, New York, NY 10019, 212.839.5300; One South Dearborn, Chicago, IL 60603, 312.853.7000; and 1501 K Street, N.W., Washington, D.C. 20005, 202.736.8000.